Vitamin D and Calcium attenuate bone loss with antiretroviral therapy initiation: A Randomized Trial

Annals of Internal Medicine

Volumn 162, Issue 12, 2015, Pages 815-824

  Overton, Edgar Turner ^a   Chan, Ellen S ^b   Brown, Todd T ^c   Tebas, Pablo ^d   McComsey, Grace A ^e   Melbourne, Kathleen M ^f   Napoli, Andrew ^g   Hardin, William Royce ^h   Ribaudo, Heather J ^b   Yin, Michael T ⁱ  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f Gilead Sciences   (United States)

^g BRISTOL MYERS SQUIBB   (United States)

^h DUKE UNIVERSITY   (United States)

ⁱ New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM CARBONATE; CARBOXY TERMINAL TELOPEPTIDE; CD14 ANTIGEN; COLECALCIFEROL; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INTERLEUKIN 6; PARATHYROID HORMONE; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VIRUS RNA; ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; BONE DENSITY CONSERVATION AGENT; CALCIFEDIOL;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; ASEPTIC MENINGITIS; BONE DENSITY; BONE TURNOVER; CD4 LYMPHOCYTE COUNT; CHOLECYSTITIS; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HAND PAIN; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MALLORY WEISS SYNDROME; MULTICENTER STUDY; NEPHROLITHIASIS; OSTEOLYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; SHOULDER DISLOCATION; SIDE EFFECT; VITAMIN SUPPLEMENTATION; BLOOD; CHEMICALLY INDUCED; DIETARY SUPPLEMENT; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; OSTEOPOROSIS; PHOTON ABSORPTIOMETRY; PROSPECTIVE STUDY;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-RETROVIRAL AGENTS; BIOMARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIFEDIOL; CALCIUM CARBONATE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; PROSPECTIVE STUDIES;

EID: 84932109898     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-1409     Document Type: Article

References (54)

1. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al; Swiss HIV Cohort Study (SHCS). Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14:195-207. doi:10.1111/j.1468-1293.2012.01051.x
2. Yin MT, Kendall MA, Wu X, Tassiopoulos K, Hochberg M, Huang JS, et al. Fractures after antiretroviral initiation. AIDS. 2012;26:2175-84. doi:10.1097/QAD.0b013e328359a8ca
3. Young B, Dao CN, Buchacz K, Baker R, Brooks JT; HIV Outpatient Study (HOPS) Investigators. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the U.S. general population, 2000-2006. Clin Infect Dis. 2011; 52:1061-8. doi:10.1093/cid/ciq242
4. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al; Veterans Aging Cohort Study Project Team. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6:e17217. doi:10 .1371/journal.pone.0017217
5. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825-31. doi:10.1097/QAD.0b013e32835192ae
6. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499-504. doi:10.1210/jc .2008-0828
7. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G, et al. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS. 2012;26:285-93. doi:10.1097/QAD .0b013e32834ed8a7
8. Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-7.
9. Hernandez-Vallejo SJ, Beaupere C, Larghero J, Capeau J, Lagathu C. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell. 2013;12:955-65. doi:10.1111/acel.12119
10. Yin MT, Lund E, Shah J, Zhang CA, Foca M, Neu N, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. AIDS. 2014;28: 345-53. doi:10.1097/QAD.0000000000000070
11. Brown TT, Ross AC, Storer N, Labbato D, McComsey GA. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens. Antivir Ther. 2011;16:1063-72. doi:10.3851/IMP1874
12. Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013;57:1483-8. doi:10.1093/cid/cit538
13. Bolland MJ, Grey AB, Gamble GD, Reid IR. CLINICAL Review #: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-Analysis. J Clin Endocrinol Metab. 2007;92:4522-8.
14. Vikulina T, Fan X, Yamaguchi M, Roser-Page S, Zayzafoon M, Guidot DM, et al. Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats. Proc Natl Acad Sci U S A. 2010;107:13848-53. doi:10.1073/pnas .1003020107
15. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavirritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-801. doi:10 .1093/infdis/jir188
16. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al; 903 Study Group. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
17. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al; ASSERT Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-72. doi:10.1086/656417
18. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al; ANRS 121 Hippocampe study group. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23:817-24. doi: 10.1097/QAD.0b013e328328f789
19. Recker R, Lappe J, Davies K, Heaney R. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res. 2000; 15:1965-73.
20. Aloia JF, Dhaliwal R, Shieh A, Mikhail M, Islam S, Yeh JK. Calcium and vitamin D supplementation in postmenopausal women. J Clin Endocrinol Metab. 2013;98:E1702-9. doi:10.1210/jc.2013-2121
21. Cotter AG, Mallon PW. The effects of untreated and treated HIV infection on bone disease. Curr Opin HIV AIDS. 2014;9:17-26. doi:10.1097/COH.0000000000000028
22. Havens PL, Stephensen CB, Hazra R, Flynn PM, Wilson CM, Rutledge B, et al; Adolescent Medicine Trials Network (ATN) for HIV/ AIDS Interventions 063 study team. Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial. Clin Infect Dis. 2012;54:1013-25. doi:10.1093/cid/cir968
23. Havens PL, Kiser JJ, Stephensen CB, Hazra R, Flynn PM, Wilson CM, et al; Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 063 Study Team. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 2013;57:5619-28. doi:10 .1128/AAC.01096-13
24. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15:425-9. doi:10.3851/IMP1502
25. Wohl DA, Orkin C, Doroana M, Pilotto JH, Sungkanuparph S, Yeni P, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a phase III trial (ECHO). Antivir Ther. 2014;19:191-200. doi:10.3851/IMP2721
26. Jones G, Prosser DE, Kaufmann M. Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res. 2014;55:13-31. doi:10.1194/jlr.R031534
27. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al; Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60.
28. Beard JA, Bearden A, Striker R. Vitamin D and the anti-viral state. J Clin Virol. 2011;50:194-200. doi:10.1016/j.jcv .2010.12.006
29. Lang CL, Wang MH, Chiang CK, Lu KC. Vitamin D and the immune system from the nephrologist's viewpoint. ISRN Endocrinol. 2014;2014:105456. doi:10.1155/2014/105456
30. Jeng L, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009;7:28. doi:10.1186/1479-5876-7-28
31. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, et al. Vitamin D-directed rheostatic regulation of monocyte antibacterial responses. J Immunol. 2009;182:4289-95. doi:10.4049/jimmunol.0803736
32. van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol. 2005;97: 93-101.
33. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O'Garra A. 1alpha, 25-Dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol. 2001;167:4974-80.
34. Longenecker CT, Jiang Y, Orringer CE, Gilkeson RC, Debanne S, Funderburg NT, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS. 2014;28:969-77. doi:10.1097/QAD.0000000000000158
35. Kelesidis T, Kendall MA, Yang OO, Hodis HN, Currier JS. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis. 2012;206:1558-67. doi:10.1093/infdis/jis545
36. Kaplan RC, Sinclair E, Landay AL, Lurain N, Sharrett AR, Gange SJ, et al. T cell activation predicts carotid artery stiffness among HIV-infected women. Atherosclerosis. 2011;217:207-13. doi:10.1016/j.atherosclerosis.2011.03.011
37. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51-83. doi:10.1016/B978-0-12-407707-2.00002-3
38. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85:6-18.
39. Vieth R, Bischoff-Ferrari H, Boucher BJ, Dawson-Hughes B, Garland CF, Heaney RP, et al. The urgent need to recommend an intake of vitamin D that is effective [Editorial]. Am J Clin Nutr. 2007;85:649-50.
40. Mitka M. More evidence on low vitamin D levels fuels push to revise recommended intake. JAMA. 2009;302:2527-8. doi:10.1001/jama.2009.1788
41. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D and Fluoride. Washington, DC: National Academies Pr; 1997.
42. Longenecker CT, Hileman CO, Carman TL, Ross AC, Seydafkan S, Brown TT, et al. Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther. 2012;17:613-21. doi:10.3851/IMP1983
43. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al; INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203. doi:10.1371/journal.pmed .0050203
44. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201:1788-95. doi:10.1086/652749
45. Kumar A, Abbas W, Herbein G. TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? Mediators Inflamm. 2013;2013:484378. doi:10.1155/2013/484378
46. Longenecker CT, Jiang Y, Orringer CE, Gilkeson RC, Debanne S, Funderburg NT, et al. Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. AIDS. 2014;28:969-77. doi:10.1097/QAD.0000000000000158
47. Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med. 2007;146:87-95.
48. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937-46. doi:10.1086/656412
49. Liu AY, Vittinghoff E, Sellmeyer DE, Irvin R, Mulligan K, Mayer K, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6:e23688. doi:10 .1371/journal.pone.0023688
50. Siberry GK, Jacobson DL, Kalkwarf H, Wu JW, DiMeglio LA, Yogev R, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate. Topics in Antiviral Medicine. 2014;22(e1):35.
51. Rosenvinge MM, Gedela K, Copas AJ, Wilkinson A, Sheehy CA, Bano G, et al. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr. 2010;54:496-9.
52. Welz T, Childs K, Ibrahim F, Poulton M, Taylor CB, Moniz CF, et al. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS. 2010;24:1923-8. doi:10.1097/QAD.0b013e32833c3281
53. Khoo AL, Chai L, Koenen H, Joosten I, Netea M, van der Ven A. Translating the role of vitamin D3 in infectious diseases. Crit Rev Microbiol. 2012;38:122-35. doi:10.3109/1040841X.2011.622716
54. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Melbourne K, et al. Inflammation markers after randomization to abacavir/ lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ ritonavir. AIDS. 2012;26:1371-85. doi:10.1097/QAD.0b013e328354f4fb